Burke J P, Martin-Perez B, Khan A, Nassif G, de Beche-Adams T, Larach S W, Albert M R, Atallah S
Center for Colon and Rectal Surgery, Florida Hospital, Orlando, Florida, USA.
Colorectal Dis. 2016 Jun;18(6):570-7. doi: 10.1111/codi.13263.
Minimally invasive approaches to proctectomy for rectal cancer have not been widely adopted due to inherent technical challenges. A modification of traditional transabdominal mobilization, termed transanal total mesorectal excision (TaTME), has the potential to improve access to the distal rectum. The aim of the current study is to assess outcomes following TaTME for rectal cancer.
This is a retrospective analysis of a prospectively maintained database of consecutive patients who underwent TaTME for rectal cancer at a single institution. The study period was from 1 March 2012 to 31 July 2015.
During the study period 50 patients underwent TaTME. The median tumour distance from the anal verge was 4.4 (3.0-5.5) cm. The rate of conversion from a planned minimally invasive approach was 2.2%. The median operative time was 267.0 (227.0-331.0) min. The median lymph node yield was 18.0 (12.0-23.8), the macroscopic quality assessment of the resected specimen was incomplete in 2% and the circumferential resection margin positivity rate was 4%. Intra-operative morbidity occurred in 6% and the 30 day morbidity rate was 36%. The median length of stay was 4.5 (4.0-8.0) days. The median follow-up was 15.1 (7.0-23.2) months; two patients have developed a local recurrence and eight patients have developed distant recurrence.
These data suggest that TaTME for rectal cancer is feasible with an acceptable pathological outcome and morbidity profile. Further data on functional and long-term survival outcomes are required.
由于存在固有的技术挑战,直肠癌直肠切除术的微创方法尚未得到广泛应用。一种对传统经腹游离术的改良方法,即经肛门全直肠系膜切除术(TaTME),有可能改善对直肠远端的显露。本研究的目的是评估直肠癌TaTME术后的结局。
这是一项对在单一机构接受直肠癌TaTME的连续患者的前瞻性维护数据库进行的回顾性分析。研究期间为2012年3月1日至2015年7月31日。
在研究期间,50例患者接受了TaTME。肿瘤距肛缘的中位距离为4.4(3.0 - 5.5)cm。计划的微创方法中转开腹率为2.2%。中位手术时间为267.0(227.0 - 331.0)分钟。中位淋巴结收获数为18.0(12.0 - 23.8),切除标本的宏观质量评估2%不完整,环周切缘阳性率为4%。术中并发症发生率为6%,30天并发症发生率为36%。中位住院时间为4.5(4.0 - 8.0)天。中位随访时间为15.1(7.0 - 23.2)个月;2例患者出现局部复发,8例患者出现远处复发。
这些数据表明,直肠癌TaTME是可行的,病理结局和并发症情况可接受。需要进一步获取关于功能和长期生存结局的数据。